Relationship between donepezil and fracture risk in patients with dementia with Lewy bodies
Geriatrics & Gerontology International · 2024
DOI: 10.1111/ggi.14929 ↗Kurz gefasst
Fachartikel in der Zeitschrift Geriatrics & Gerontology International, 2024. Verfasst von Shoya Matsumoto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Donepezil, Lewy Body Disease, Hip Fractures, Propensity Score. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Aim
Patients with dementia with Lewy bodies (DLB) are at a high risk for falls and fractures. Although cholinesterase inhibitors reportedly are effective in suppressing the progression of cognitive symptoms in DLB patients, their effects on fracture risk remain unclarified. This study aimed to evaluate the association between donepezil use and hip fracture risk in older patients with DLB.
Methods
Using the Japanese insurance claim database, we collected the data of patients aged ≥65 years with DLB from April 2012 to March 2019. After propensity score matching, we compared the fracture rate over 3 years between DLB patients receiving donepezil and those not receiving antidementia drugs.
Results
Altogether, 24 022 239 individuals aged ≥65 years were newly registered from April 2012 to March 2016 and had verifiable information from 6 months before to 3 years after the registration. We identified 6634 pure‐DLB patients and analyzed the data of 1182 propensity score‐matched pairs. The characteristics, including age, sex, fracture history, osteoporosis, and bone mineral density test rate, of the two groups were well balanced by propensity score matching. The incidence rate of hip fracture was significantly lower in DLB patients receiving donepezil than in those not receiving antidementia drugs (0.60 vs. 1.44/100 person‐years, P < 0.001), whereas that of vertebral fractures was the same.
Conclusions
Donepezil administration in Japanese people aged ≥65 years with DLB was significantly associated with a decreased risk of hip fracture. Donepezil may provide new benefits to DLB patients. Geriatr Gerontol Int 2024; 24: 782–788 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Tohoku University School of Medicine, Department of Health Administration and Policy, Sendai, Japan.
- National Database Japan - Osteoporosis Management (NDBJ-OS) Study Group, Kindai University Faculty of Medicine, Osaka, Japan.
- Department of Hygiene and Public Health, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
- Department of Orthopedic Surgery, Asahi General Hospital, Toyama, Japan.
- Department of Regulatory Science, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
ORCID-Profile: Shunichi Nakatoh, Masahiro Akishita, Sumito Ogawa
Zitieren
APA
Matsumoto, S., Yakabe, M., Hosoi, T., Fujimori, K., Tamaki, J., Nakatoh, S., Ishii, S., Okimoto, N., Akishita, M., Iki, M., & Ogawa, S. (2024). Relationship between donepezil and fracture risk in patients with dementia with Lewy bodies. Geriatrics & Gerontology International. https://doi.org/10.1111/ggi.14929
Vancouver
Matsumoto S, Yakabe M, Hosoi T, Fujimori K, Tamaki J, Nakatoh S, et al. Relationship between donepezil and fracture risk in patients with dementia with Lewy bodies. Geriatrics & Gerontology International. 2024. doi:10.1111/ggi.14929
BibTeX
@article{Matsumoto2024,
author = {Matsumoto, Shoya and Yakabe, Mitsutaka and Hosoi, Tatsuya and Fujimori, Kenji and Tamaki, Junko and Nakatoh, Shunichi and Ishii, Shigeyuki and Okimoto, Nobukazu and Akishita, Masahiro and Iki, Masayuki and Ogawa, Sumito},
title = {Relationship between donepezil and fracture risk in patients with dementia with Lewy bodies},
journal = {Geriatrics & Gerontology International},
year = {2024},
doi = {10.1111/ggi.14929}
}
EUVIMED